While the condition can impact quality of life and mental health, seeking treatment and support can make a powerful ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

In China, the number of patients with atopic dermatitis continues to ... and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

In the last few months, Pfizer has won approvals in the EU and US for JAK inhibitor Cibinqo (abrocitinib) as a treatment for moderate-to-severe atopic dermatitis in adults who cannot get relief ...

Biosion’s BSI-045B, a novel anti-TSLP monoclonal antibody, is currently in clinical development in the United States for treating moderate-to-severe atopic dermatitis ... indicative of its potential ...

Learn about the benefits and risks of probiotic supplements and how to choose the best one for your health goals.

Approximately one third of parents of children with atopic dermatitis (AD ... do not currently recommend elimination diets as a treatment for AD, said Nadia Makkoukdji, MD, a pediatrician at ...